London
· Delayed Price · Currency is GBP · Price in GBXRenalytix Statistics
Total Valuation
Renalytix has a market cap or net worth of GBP 12.44 million. The enterprise value is 15.49 million.
| Market Cap | 12.44M |
| Enterprise Value | 15.49M |
Important Dates
The last earnings date was Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Renalytix has 165.93 million shares outstanding. The number of shares has increased by 31.59% in one year.
| Shares Outstanding | 165.93M |
| Shares Change (YoY) | +31.59% |
| Shares Change (QoQ) | +41.48% |
| Owned by Insiders (%) | 5.18% |
| Owned by Institutions (%) | 78.28% |
| Float | 131.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.48 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.59 |
| EV / Sales | 8.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.65 |
Financial Position
The company has a current ratio of 0.53
| Current Ratio | 0.53 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.28 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -93.54% |
| Return on Capital (ROIC) | -182.66% |
| Revenue Per Employee | 17,757 |
| Profits Per Employee | -259,537 |
| Employee Count | 102 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.21% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -84.21% |
| 50-Day Moving Average | 10.74 |
| 200-Day Moving Average | 19.09 |
| Relative Strength Index (RSI) | 18.72 |
| Average Volume (20 Days) | 170,097 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Renalytix had revenue of GBP 1.81 million and -26.47 million in losses. Loss per share was -0.25.
| Revenue | 1.81M |
| Gross Profit | 123,438 |
| Operating Income | -22.86M |
| Pretax Income | -26.47M |
| Net Income | -26.47M |
| EBITDA | -22.65M |
| EBIT | -22.86M |
| Loss Per Share | -0.25 |
Balance Sheet
The company has 3.70 million in cash and 6.75 million in debt, giving a net cash position of -3.05 million or -0.02 per share.
| Cash & Cash Equivalents | 3.70M |
| Total Debt | 6.75M |
| Net Cash | -3.05M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -6.21M |
| Book Value Per Share | -0.04 |
| Working Capital | -4.25M |
Cash Flow
In the last 12 months, operating cash flow was -23.83 million and capital expenditures -3,165, giving a free cash flow of -23.83 million.
| Operating Cash Flow | -23.83M |
| Capital Expenditures | -3,165 |
| Free Cash Flow | -23.83M |
| FCF Per Share | -0.14 |
Margins
| Gross Margin | 6.82% |
| Operating Margin | -1,261.90% |
| Pretax Margin | -1,461.42% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,315.64% |
Dividends & Yields
Renalytix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.59% |
| Shareholder Yield | -31.59% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Renalytix has an Altman Z-Score of -47.39. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -47.39 |
| Piotroski F-Score | n/a |